--Bayer AG's (BAYN.XE) digestive medication Iberogast is at the center of an investigation by the Cologne public prosecutor's office for a possible connection with the death of a person who took the medication, German business magazine Handelsblatt reports.
--According to the publication, the conglomerate refused to add warnings about possible liver damage and failure to the drug's package leaflet for years.
--The company only added them last year, when it became known that a woman in Germany died of liver failure and interior bleeding who previously took the medication, Handelsblatt reports.
--Bayer wasn't immediately available for comment.
Full story (in German): https://bit.ly/2Y9Sncd
Write to Barcelona editors at firstname.lastname@example.org